Equities Analysts Offer Predictions for NBIX Q3 Earnings

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Investment analysts at Leerink Partnrs dropped their Q3 2025 earnings per share (EPS) estimates for shares of Neurocrine Biosciences in a report issued on Monday, February 17th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of $1.28 per share for the quarter, down from their prior forecast of $1.29. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.28 per share. Leerink Partnrs also issued estimates for Neurocrine Biosciences’ Q4 2025 earnings at $1.27 EPS and FY2026 earnings at $6.50 EPS.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%.

Other analysts have also recently issued research reports about the stock. Guggenheim decreased their price target on shares of Neurocrine Biosciences from $165.00 to $163.00 and set a “buy” rating on the stock in a research note on Monday, February 10th. StockNews.com cut shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Royal Bank of Canada cut their price objective on shares of Neurocrine Biosciences from $154.00 to $148.00 and set a “sector perform” rating on the stock in a research note on Friday, February 7th. Piper Sandler reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Neurocrine Biosciences in a report on Monday, December 23rd. Finally, William Blair reiterated an “outperform” rating on shares of Neurocrine Biosciences in a report on Friday, February 7th. Five analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $166.90.

Neurocrine Biosciences Stock Performance

NBIX stock opened at $113.97 on Wednesday. Neurocrine Biosciences has a 52-week low of $110.95 and a 52-week high of $157.98. The firm has a market capitalization of $11.36 billion, a price-to-earnings ratio of 34.64, a PEG ratio of 0.78 and a beta of 0.33. The firm has a 50 day moving average price of $137.55 and a 200-day moving average price of $130.19.

Insider Buying and Selling at Neurocrine Biosciences

In related news, insider Jude Onyia sold 2,331 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $126.29, for a total transaction of $294,381.99. Following the completion of the transaction, the insider now directly owns 15,449 shares in the company, valued at approximately $1,951,054.21. The trade was a 13.11 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Kevin Charles Gorman sold 2,707 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $152.92, for a total value of $413,954.44. Following the completion of the transaction, the director now directly owns 517,030 shares in the company, valued at approximately $79,064,227.60. This represents a 0.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 236,600 shares of company stock worth $34,348,261 over the last ninety days. Insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of hedge funds have recently made changes to their positions in the stock. Caprock Group LLC purchased a new position in shares of Neurocrine Biosciences in the fourth quarter worth about $236,000. Plato Investment Management Ltd boosted its stake in Neurocrine Biosciences by 2,481.9% during the third quarter. Plato Investment Management Ltd now owns 10,973 shares of the company’s stock worth $1,263,000 after buying an additional 10,548 shares during the last quarter. Swiss National Bank lifted its stake in shares of Neurocrine Biosciences by 1.4% in the 3rd quarter. Swiss National Bank now owns 298,700 shares of the company’s stock valued at $34,416,000 after purchasing an additional 4,100 shares during the last quarter. Tri Ri Asset Management Corp acquired a new position in shares of Neurocrine Biosciences in the 3rd quarter valued at $3,236,000. Finally, KBC Group NV lifted its stake in Neurocrine Biosciences by 78.3% during the 3rd quarter. KBC Group NV now owns 18,972 shares of the company’s stock worth $2,186,000 after acquiring an additional 8,332 shares in the last quarter. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.